Stock Screener App

Frei -

Installieren

4.59

2.23% 0.10

after-market

Handel nachbörslich: 4.57 -0.02 -0.44%

Emergent Biosolutions Inc (EBS)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten

Emergent Biosolutions Inc. (NYSE:EBS) Given Average Rating of "Hold" by Analysts - MarketBeat

Q2 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus

Q4 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus

Q1 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus

Emergent BioSolutions Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus

American Century group reports 5.4% Emergent BioSolutions (EBS) ownership on Schedule 13G - Stock Titan

Emergent Biosolutions (EBS) Earnings Date and Reports 2026 $EBS - MarketBeat

Levi & Korsinsky Notifies Investors of Pending - GlobeNewswire

Emergent Biosolutions (NYSE:EBS) Rating Increased to Hold at Zacks Research - MarketBeat

Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript - AOL.com

EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS) - Business Wire

Emergent BioSolutions (EBS) EVP Stephanie Duatschek details stock and option holdings - Stock Titan

Trade Desk, Papa John's, Emergent BioSolutions Hit 52-Week Lows as Weak Results Trigger Analyst Downgrades - finance.biggo.com

EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions - PR Newswire

EMERGENT BIOSOLUTIONS INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $10 FROM $12 - webull.com

Why Did TTD, PZZA, EBS Stocks Plummet To 52 Week Lows? - Stocktwits

Emergent BioSolutions cuts FY2026 revenue forec... - Pluang

Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS) - PR Newswire

H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Cuts Target Price to $10 - Moomoo

H.C. Wainwright cuts Emergent BioSolutions stock price target on revenue outlook - Investing.com Nigeria

Emergent Biosolutions (NYSE:EBS) Given New $10.00 Price Target at HC Wainwright - MarketBeat

EBS Maintained by HC Wainwright & Co. -- Price Target Lowered to $10 - GuruFocus

Emergent BioSolutions Inc (EBS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Emergent BioSolutions (EBS) Stock Sinks As NARCAN Impairment Deepens Losses - Sahm

Emergent BioSolutions Inc (EBS) Stock News Today - TradingKey

Emergent Biosolutions Q2 Earnings Call Highlights - MarketBeat

Watch Out on Emergent BioSolutions Inc.: Strong Operational Recovery Tempered by Commercial Headwinds and Strategic Reset - Kalkine

Despite Hitting US$5.31, Emergent BioSolutions Insiders Still Sold Too Soon - Moomoo

Pacer Advisors Inc. Purchases Shares of 416,191 Emergent Biosolutions Inc. $EBS - MarketBeat

Emergent BioSolutions Inc. (EBS): Investor Outlook Reveals 125.99% Potential Upside - DirectorsTalk Interviews

Dimensional Fund Advisors LP Has $22.88 Million Position in Emergent Biosolutions Inc. $EBS - MarketBeat

Emergent BioSolutions Shares Plunge After 2026 Guidance Cut, Restructuring - Moomoo

Emergent BioSolutions Announces Restructuring Amid Turnaround Efforts - The Globe and Mail

Emergent BioSolutions laying off dozens, shedding real estate as Narcan competition strains profits - The Business Journals

Emergent BioSolutions | 10-Q: Q2 2026 Earnings Report - Moomoo

Emergent Bio stock slips despite Q2 beat (EBS:NYSE) - Seeking Alpha

Emergent BioSolutions Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Emergent BioSolutions Inc. 2026: Revenue $234.3M, EPS ($3.49) — 10-Q Summary - TradingView

Emergent BioSolutions (NYSE: EBS) posts Q2 loss, plans cost-cutting - Stock Titan

Emergent Q2 2026 slides: strong quarter, but guidance cut sparks selloff - Investing.com

Emergent Biosolutions (NYSE:EBS) Announces Quarterly Earnings Results - MarketBeat

Earnings call transcript: Emergent BioSolutions Q2 2026 revenue tops guidance - Investing.com

Emergent BioSolutions Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Is Emergent BioSolutions Inc (EBS) Overvalued After Q2 Earnings - GuruFocus

Emergent Q2 2026 slides: MCM strength offset by naloxone pressure - Investing.com

EBS: Strong Q2 driven by MCM, but naloxone competition prompts lower guidance and restructuring - TradingView

Emergent BioSolutions Inc. 2026 Q2ResultsEarnings Call Presentation (NYSE:EBS) 2026-08-05 - Seeking Alpha

Emergent Q2 2026 earnings: MCM growth contrasts with NARCAN impairment - TradingKey

Q2 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus

Emergent BioSolutions Reports Second Quarter 2026 Financial Results - The Manila Times

Emergent Biosolutions: Q2 Earnings Snapshot - Yahoo Finance

Emergent BioSolutions swings to Q2 loss on impairment charge; to cut jobs - TradingView

Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment - marketscreener.com

Emergent BioSolutions Inc. Reports Impairment of Long-Lived Assets for the Second Quarter Ended June 30, 2026 - marketscreener.com

Emergent Biosolutions Inc. Announces Management Changes - marketscreener.com

Emergent BioSolutions Inc expected to post earnings of 11 cents a shareEarnings Preview - TradingView

Emergent BioSolutions Inc. (EBS) Stock Analysis: A 65% Upside Potential Despite Challenges - DirectorsTalk Interviews

Vanguard Capital Management (EBS) discloses 4.92% Emergent BioSolutions ownership - Stock Titan

Emergent Biosolutions (EBS) Projected to Post Earnings on Wednesday - MarketBeat

BlackRock (NYSE: BLK) reports 9.0% ownership of Emergent BioSolutions (EBS) stock - Stock Titan

EBS|Emergent BioSolutions Inc|Price:7.325|Chg%:+0.065 - TradingKey

Emergent BioSolutions Inc (EBS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Emergent BioSolutions Inc (EBS) Cash Flow - TradingKey

Emergent BioSolutions Inc (EBS) Income Statement - TradingKey

EBS|Emergent BioSolutions Inc|Price:7.260| - TradingKey

ALKS

$49.06

0.79%

RDY

$12.27

1.21%

ELAN

$23.67

5.15%

NBIX

$152.72

1.26%

VTRS

$16.23

1.18%

UTHR

$499.73

0.31%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters